Back to results
US 2013/0156757 A1Published application
Targeting vegf-b regulation of fatty acid transporters to modulate human diseases
AssigneeLudwig Institute for Cancer Research
InventorUlf Eriksson
Life of this patent
Estimating the term…
Abstract
The present invention provides materials and methods for modulating FATP expression and/or activity in vivo. The materials and methods have numerous diagnostic, prophylactic, and therapeutic applications for various diseases and conditions that are influenced by FATPs, or characterized by excessive or inadequate FATP expression or activity.
Claims10
-38. (canceled)
A method of treating dyslipidemia in a human subject comprising administering to a human subject in need of such treatment a VEGF-B inhibitor selected from:
- (a) an anti-VEGF-B antibody or antigen-binding fragment thereof;
- and
- (b) an anti-sense oligonucleotide that inhibits VEGF-B transcription or translation.
Dependencies are inferred from the claim text.